Who Buys Lenvatinib from India — 242 Importers Behind a $2.1M Market

The importation of Lenvatinib from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like STR International Trading Co., Ltd. in Thailand function as intermediaries, procuring Lenvatinib in bulk to supply to healthcare providers and pharmacies. Their purchasing patterns are characterized by large, regular orders to maintain a steady supply chain.

• Hospital Groups: Organizations such as LEK Pharmaceuticals D.D. in Slovenia represent hospital networks that import Lenvatinib directly for patient treatment. Their procurement is typically based on patient demand and treatment protocols, leading to consistent, volume-based orders.

• Re-exporters: Companies like Radeep Services in Singapore may act as re-exporters, importing Lenvatinib for redistribution to neighboring regions. Their buying behavior is influenced by regional demand fluctuations, resulting in variable order sizes and frequencies.

• Government Procurement: Entities such as "To the Import Manager" in the United Arab Emirates likely represent government procurement agencies responsible for national healthcare supplies. Their purchasing is often conducted through formal tenders, focusing on large-scale, cost-effective procurement to meet public health needs.

Understanding these segments is crucial for tailoring market strategies, ensuring efficient supply chain management, and meeting the specific needs of each buyer category.

Importing Lenvatinib into the top five importing countries involves navigating specific regulatory frameworks:

• Brazil:
• Regulatory Authority: Agência Nacional de Vigilância Sanitária (ANVISA).
• Import Registration Process: Requires submission of a comprehensive dossier, including clinical data and manufacturing details, followed by ANVISA's evaluation.
• Estimated Timeline: Approximately 6 to 12 months, depending on dossier completeness and ANVISA's review capacity.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 are subject to a standard import duty of 8%, with potential reductions under specific trade agreements.

• Slovenia:
• Regulatory Authority: Javna Agencija Republike Slovenije za Zdravila in Medicinske Pripomočke (JAZMP).
• Import Registration Process: Involves submission of an application with supporting documents, including quality, safety, and efficacy data, for JAZMP's assessment.
• Estimated Timeline: Typically 6 to 9 months, subject to the complexity of the application and JAZMP's workload.
• Import Tariff/Duty: As an EU member, Slovenia applies the EU's Common External Tariff, generally 0% for pharmaceutical products under HS Code 30049099.

• Thailand:
• Regulatory Authority: Thai Food and Drug Administration (Thai FDA).
• Import Registration Process: Requires submission of a registration dossier, including product specifications and clinical data, followed by Thai FDA's evaluation.
• Estimated Timeline: Approximately 8 to 12 months, depending on the completeness of the submission and regulatory review processes.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 are generally subject to an import duty of 0%, promoting access to essential medicines.

• United Arab Emirates (UAE):
• Regulatory Authority: Ministry of Health and Prevention (MOHAP).
• Import Registration Process: Involves submission of an application with detailed product information, including manufacturing and clinical data, for MOHAP's review.
• Estimated Timeline: Typically 6 to 9 months, contingent on the application's complexity and MOHAP's review schedule.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 are generally exempt from import duties, facilitating access to essential medicines.

• Singapore:
• Regulatory Authority: Health Sciences Authority (HSA).
• Import Registration Process: Requires submission of a registration dossier, including quality, safety, and efficacy data, followed by HSA's evaluation.
• Estimated Timeline: Approximately 9 to 12 months, depending on the completeness of the submission and HSA's review processes.
• Import Tariff/Duty: Singapore imposes a 0% import duty on pharmaceutical products under HS Code 30049099, supporting the availability of essential medicines.

Navigating these regulatory landscapes is essential for successful market entry and sustained supply of Lenvatinib in these regions.

The demand for Lenvatinib across importing countries is influenced by several key factors:

• Disease Prevalence: Lenvatinib is primarily used in the treatment of various cancers, including thyroid, renal cell, and hepatocellular carcinomas. The prevalence of these cancers in importing countries directly impacts demand. For instance, the increasing incidence of thyroid cancer globally has heightened the need for effective treatments like Lenvatinib.

• Government Healthcare Programs: Many countries have implemented healthcare initiatives aimed at improving cancer care. Programs that subsidize or fully cover the cost of essential medicines enhance patient access to treatments like Lenvatinib.

• Universal Health Coverage Expansion: Efforts to achieve universal health coverage (UHC) have led to increased inclusion of cancer treatments in national health insurance schemes, thereby boosting demand for Lenvatinib.

• WHO Essential Medicines List Procurement: Inclusion of cancer treatments in the WHO Essential Medicines List encourages countries to prioritize their procurement, ensuring broader access.

• Tender-Based Purchasing: Government and institutional tenders for bulk purchasing of pharmaceuticals often include Lenvatinib, reflecting its recognized therapeutic value and driving substantial demand.

With 242 buyers across 74 countries, the global reach of Lenvatinib underscores its critical role in cancer treatment and the importance of understanding these demand drivers to effectively address market opportunities.

The importation of Lenvatinib from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like STR International Trading Co., Ltd. in Thailand function as intermediaries, procuring Lenvatinib in bulk to supply to healthcare providers and pharmacies. Their purchasing patterns are characterized by large, regular orders to maintain a steady supply chain.

• Hospital Groups: Organizations such as LEK Pharmaceuticals D.D. in Slovenia represent hospital networks that import Lenvatinib directly for patient treatment. Their procurement is typically based on patient demand and treatment protocols, leading to consistent, volume-based orders.

• Re-exporters: Companies like Radeep Services in Singapore may act as re-exporters, importing Lenvatinib for redistribution to neighboring regions. Their buying behavior is influenced by regional demand fluctuations, resulting in variable order sizes and frequencies.

• Government Procurement: Entities such as "To the Import Manager" in the United Arab Emirates likely represent government procurement agencies responsible for national healthcare supplies. Their purchasing is often conducted through formal tenders, focusing on large-scale, cost-effective procurement to meet public health needs.

Understanding these segments is crucial for tailoring market strategies, ensuring efficient supply chain management, and meeting the specific needs of each buyer category.

Importing Lenvatinib into the top five importing countries involves navigating specific regulatory frameworks:

• Brazil:
• Regulatory Authority: Agência Nacional de Vigilância Sanitária (ANVISA).
• Import Registration Process: Requires submission of a comprehensive dossier, including clinical data and manufacturing details, followed by ANVISA's evaluation.
• Estimated Timeline: Approximately 6 to 12 months, depending on dossier completeness and ANVISA's review capacity.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 are subject to a standard import duty of 8%, with potential reductions under specific trade agreements.

• Slovenia:
• Regulatory Authority: Javna Agencija Republike Slovenije za Zdravila in Medicinske Pripomočke (JAZMP).
• Import Registration Process: Involves submission of an application with supporting documents, including quality, safety, and efficacy data, for JAZMP's assessment.
• Estimated Timeline: Typically 6 to 9 months, subject to the complexity of the application and JAZMP's workload.
• Import Tariff/Duty: As an EU member, Slovenia applies the EU's Common External Tariff, generally 0% for pharmaceutical products under HS Code 30049099.

• Thailand:
• Regulatory Authority: Thai Food and Drug Administration (Thai FDA).
• Import Registration Process: Requires submission of a registration dossier, including product specifications and clinical data, followed by Thai FDA's evaluation.
• Estimated Timeline: Approximately 8 to 12 months, depending on the completeness of the submission and regulatory review processes.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 are generally subject to an import duty of 0%, promoting access to essential medicines.

• United Arab Emirates (UAE):
• Regulatory Authority: Ministry of Health and Prevention (MOHAP).
• Import Registration Process: Involves submission of an application with detailed product information, including manufacturing and clinical data, for MOHAP's review.
• Estimated Timeline: Typically 6 to 9 months, contingent on the application's complexity and MOHAP's review schedule.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 are generally exempt from import duties, facilitating access to essential medicines.

• Singapore:
• Regulatory Authority: Health Sciences Authority (HSA).
• Import Registration Process: Requires submission of a registration dossier, including quality, safety, and efficacy data, followed by HSA's evaluation.
• Estimated Timeline: Approximately 9 to 12 months, depending on the completeness of the submission and HSA's review processes.
• Import Tariff/Duty: Singapore imposes a 0% import duty on pharmaceutical products under HS Code 30049099, supporting the availability of essential medicines.

Navigating these regulatory landscapes is essential for successful market entry and sustained supply of Lenvatinib in these regions.

The demand for Lenvatinib across importing countries is influenced by several key factors:

• Disease Prevalence: Lenvatinib is primarily used in the treatment of various cancers, including thyroid, renal cell, and hepatocellular carcinomas. The prevalence of these cancers in importing countries directly impacts demand. For instance, the increasing incidence of thyroid cancer globally has heightened the need for effective treatments like Lenvatinib.

• Government Healthcare Programs: Many countries have implemented healthcare initiatives aimed at improving cancer care. Programs that subsidize or fully cover the cost of essential medicines enhance patient access to treatments like Lenvatinib.

• Universal Health Coverage Expansion: Efforts to achieve universal health coverage (UHC) have led to increased inclusion of cancer treatments in national health insurance schemes, thereby boosting demand for Lenvatinib.

• WHO Essential Medicines List Procurement: Inclusion of cancer treatments in the WHO Essential Medicines List encourages countries to prioritize their procurement, ensuring broader access.

• Tender-Based Purchasing: Government and institutional tenders for bulk purchasing of pharmaceuticals often include Lenvatinib, reflecting its recognized therapeutic value and driving substantial demand.

With 242 buyers across 74 countries, the global reach of Lenvatinib underscores its critical role in cancer treatment and the importance of understanding these demand drivers to effectively address market opportunities.